Citadel Advisors
HUMA icon

Citadel Advisors’s Humacyte HUMA Stock Holding History

Citadel Advisors’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$235K Buy
301,400
+137,500
+84% +$127K ﹤0.01% 11684
2026
Q1 		$99.4K Sell
163,900
-86,800
-35% -$90.2K ﹤0.01% 12027
2025
Q4 		$241K Buy
250,700
+73,800
+42% +$105K ﹤0.01% 10637
2025
Q3 		$308K Sell
176,900
-469,600
-73% -$920K ﹤0.01% 10311
2025
Q2 		$1.35M Buy
646,500
+20,800
+3% +$40K ﹤0.01% 6465
2025
Q1 		$1.07M Buy
625,700
+499,800
+397% +$1.88M ﹤0.01% 6820
2024
Q4 		$636K Buy
125,900
+73,900
+142% +$366K ﹤0.01% 8014
2024
Q3 		$283K Buy
52,000
+39,600
+319% +$261K ﹤0.01% 9459
2024
Q2 		$59.5K Sell
12,400
-3,200
-21% -$16.7K ﹤0.01% 11569
2024
Q1 		$48.5K Buy
15,600
+14,100
+940% +$47.4K ﹤0.01% 12199
2023
Q4 		$4.26K Hold
1,500
– – ﹤0.01% 13527
2023
Q3 		$4.39K Buy
1,500
+700
+88% +$2.32K ﹤0.01% 13487
2023
Q2 		$2.29K Buy
+800
New +$2.88K ﹤0.01% 13803
2023
Q1 		– Sell
-12,700
Closed -$26.8K – 15039
2022
Q4 		$26.8K Sell
12,700
-10,800
-46% -$32.8K ﹤0.01% 12877
2022
Q3 		$77K Buy
23,500
+8,500
+57% +$32.6K ﹤0.01% 11305
2022
Q2 		$48K Sell
15,000
-15,900
-51% -$88.4K ﹤0.01% 11961
2022
Q1 		$218K Buy
30,900
+4,200
+16% +$24.5K ﹤0.01% 11315
2021
Q4 		$194K Buy
26,700
+3,900
+17% +$38.6K ﹤0.01% 11889
2021
Q3 		$265K Buy
+22,800
New +$261K ﹤0.01% 11338

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors's HUMA Position: Q2 2026 in Review

Citadel Advisors opened a new position in Humacyte (HUMA) in Q2 2026: 1,443,376 shares worth $1.13M. The stake represents ﹤0.01% of the portfolio and ranks #7917 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in HUMA as recently as Q4 2025.

Citadel Advisors first reported a position in HUMA in Q4 2021 and has held it in 17 quarters since. The position peaked at $4.96M in Q1 2025. 163 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Citadel Advisors held 1,443,376 shares of Humacyte worth $1.13M as of Q2 2026.
  • Humacyte was a new Citadel Advisors position in Q2 2026.
  • Humacyte made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #7917 holding.
  • Citadel Advisors first reported a position in Humacyte in Q4 2021 and has held it in 17 quarters since.
  • Citadel Advisors's Humacyte position peaked at $4.96M in Q1 2025.
  • 163 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.